检索结果 - Z. Szijgyarto

  • Showing 1 - 1 results of 1
Refine Results
  1. 1
    57O Randomized double-blind phase II trial (PERLA) of dostarlimab (dostar) + chemotherapy (CT) vs pembrolizumab (pembro) + CT in metastatic non-squamous NSCLC: Primary results

    57O Randomized double-blind phase II trial (PERLA) of dostarlimab (dostar) + chemotherapy (CT) vs pembrolizumab (pembro) + CT in metastatic non-squamous NSCLC: Primary results 由 Solange Peters, S.M. Lim, A.L. Ortega Granados, G.D.J. Pinto, C.S. Fuentes, G. Lo Russo, M. Schenker, J.S. Ahn, M. Reck, Z. Szijgyarto, N. Huseinovic, E. Zografos, S. O’Donnell, F. de Marinis

    出版 2022
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: